Bronchial asthma with normal forced expiratory volume in 1 second (FEV1) compared with low FEV1

Cough variant asthma (CVA) is characterized by cough as a sole symptom and normal pulmonary function. However, it is unclear whether CVA really common among asthmatic patients with normal forced expiratory volume in 1 second (FEV1). The aim of this study was to evaluate the incidence of cough alone...

Full description

Saved in:
Bibliographic Details
Published inJournal of thoracic disease Vol. 16; no. 9; pp. 5580 - 5590
Main Authors Ohwada, Akihiko, Kitaoka, Hiroko
Format Journal Article
LanguageEnglish
Published China AME Publishing Company 30.09.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Cough variant asthma (CVA) is characterized by cough as a sole symptom and normal pulmonary function. However, it is unclear whether CVA really common among asthmatic patients with normal forced expiratory volume in 1 second (FEV1). The aim of this study was to evaluate the incidence of cough alone symptom among the subjects with normal FEV1 and to evaluate their differences from ordinary asthmatic subjects. We defined normal FEV1 as ≥90% predicted based on the article of Kotti GH. Of the patients with normal FEV1, we chose subjects without wheeze, and the duration of cough was not to ask, since the symptoms often occurred with acute exacerbation and timing of visiting a doctor depended on each patient's perception. Test for airway hyperresponsiveness was not performed in this study. Visual analogue scale (VAS) scores for cough and dyspnea, FEV1, and fractional exhaled nitric oxide (FeNO) responsiveness to inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment were compared in patients with normal FEV1 and with low FEV1 <90%. Correlations of changes in symptoms with changes of FEV1, FeNO, peripheral eosinophil count, and serum immunoglobulin E (IgE) at single time point were also examined in each group and in overall patients. The participants were 329 physician-diagnosed treatment-naive patients with asthma who were divided into 187 in normal FEV1 and 142 in low FEV1 groups. Cough without dyspnea was present in 16 patients (8.6%) in the normal FEV1 group, suggesting candidates for CVA in this analysis were quite few. Improvement in symptoms after treatment was similar between both groups. But VAS scores of dyspnea were still higher in the low FEV1 group. The degree of improvement in FEV1 after ICS/LABA treatment was less in the normal FEV1 group than in the low FEV1 group, but was still evident. Peripheral eosinophil count, serum IgE, and FeNO values before treatment were lower in the normal FEV1 group. In overall patients, improvements of symptoms after treatment were significantly correlated with FEV1 changes. Improvement of dyspnea was also significantly related to peripheral eosinophil count and change of FeNO, whereas improvement of cough was not related to these T helper 2 (Th2) response markers. Candidates for CVA among the patients with asthma with predicted FEV1 ≥90% were few. Participants with normal FEV1 respond well to ICS/LABA treatment for improvement of symptom. The change of FEV1 after treatment, and the pre-treatment blood eosinophil count, serum IgE, and FeNO were lower in normal FEV1 cases than in low FEV1 cases. These observations suggest asthmatic patients with normal FEV1, including candidates for CVA having just common mild asthma. In overall participants, symptoms of cough and dyspnea were similar, but were not identical in relation to the Th2 background.
AbstractList Cough variant asthma (CVA) is characterized by cough as a sole symptom and normal pulmonary function. However, it is unclear whether CVA really common among asthmatic patients with normal forced expiratory volume in 1 second (FEV1). The aim of this study was to evaluate the incidence of cough alone symptom among the subjects with normal FEV1 and to evaluate their differences from ordinary asthmatic subjects. We defined normal FEV1 as ≥90% predicted based on the article of Kotti GH. Of the patients with normal FEV1, we chose subjects without wheeze, and the duration of cough was not to ask, since the symptoms often occurred with acute exacerbation and timing of visiting a doctor depended on each patient's perception. Test for airway hyperresponsiveness was not performed in this study. Visual analogue scale (VAS) scores for cough and dyspnea, FEV1, and fractional exhaled nitric oxide (FeNO) responsiveness to inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment were compared in patients with normal FEV1 and with low FEV1 <90%. Correlations of changes in symptoms with changes of FEV1, FeNO, peripheral eosinophil count, and serum immunoglobulin E (IgE) at single time point were also examined in each group and in overall patients. The participants were 329 physician-diagnosed treatment-naive patients with asthma who were divided into 187 in normal FEV1 and 142 in low FEV1 groups. Cough without dyspnea was present in 16 patients (8.6%) in the normal FEV1 group, suggesting candidates for CVA in this analysis were quite few. Improvement in symptoms after treatment was similar between both groups. But VAS scores of dyspnea were still higher in the low FEV1 group. The degree of improvement in FEV1 after ICS/LABA treatment was less in the normal FEV1 group than in the low FEV1 group, but was still evident. Peripheral eosinophil count, serum IgE, and FeNO values before treatment were lower in the normal FEV1 group. In overall patients, improvements of symptoms after treatment were significantly correlated with FEV1 changes. Improvement of dyspnea was also significantly related to peripheral eosinophil count and change of FeNO, whereas improvement of cough was not related to these T helper 2 (Th2) response markers. Candidates for CVA among the patients with asthma with predicted FEV1 ≥90% were few. Participants with normal FEV1 respond well to ICS/LABA treatment for improvement of symptom. The change of FEV1 after treatment, and the pre-treatment blood eosinophil count, serum IgE, and FeNO were lower in normal FEV1 cases than in low FEV1 cases. These observations suggest asthmatic patients with normal FEV1, including candidates for CVA having just common mild asthma. In overall participants, symptoms of cough and dyspnea were similar, but were not identical in relation to the Th2 background.
Cough variant asthma (CVA) is characterized by cough as a sole symptom and normal pulmonary function. However, it is unclear whether CVA really common among asthmatic patients with normal forced expiratory volume in 1 second (FEV1). The aim of this study was to evaluate the incidence of cough alone symptom among the subjects with normal FEV1 and to evaluate their differences from ordinary asthmatic subjects.BackgroundCough variant asthma (CVA) is characterized by cough as a sole symptom and normal pulmonary function. However, it is unclear whether CVA really common among asthmatic patients with normal forced expiratory volume in 1 second (FEV1). The aim of this study was to evaluate the incidence of cough alone symptom among the subjects with normal FEV1 and to evaluate their differences from ordinary asthmatic subjects.We defined normal FEV1 as ≥90% predicted based on the article of Kotti GH. Of the patients with normal FEV1, we chose subjects without wheeze, and the duration of cough was not to ask, since the symptoms often occurred with acute exacerbation and timing of visiting a doctor depended on each patient's perception. Test for airway hyperresponsiveness was not performed in this study. Visual analogue scale (VAS) scores for cough and dyspnea, FEV1, and fractional exhaled nitric oxide (FeNO) responsiveness to inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment were compared in patients with normal FEV1 and with low FEV1 <90%. Correlations of changes in symptoms with changes of FEV1, FeNO, peripheral eosinophil count, and serum immunoglobulin E (IgE) at single time point were also examined in each group and in overall patients.MethodsWe defined normal FEV1 as ≥90% predicted based on the article of Kotti GH. Of the patients with normal FEV1, we chose subjects without wheeze, and the duration of cough was not to ask, since the symptoms often occurred with acute exacerbation and timing of visiting a doctor depended on each patient's perception. Test for airway hyperresponsiveness was not performed in this study. Visual analogue scale (VAS) scores for cough and dyspnea, FEV1, and fractional exhaled nitric oxide (FeNO) responsiveness to inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) treatment were compared in patients with normal FEV1 and with low FEV1 <90%. Correlations of changes in symptoms with changes of FEV1, FeNO, peripheral eosinophil count, and serum immunoglobulin E (IgE) at single time point were also examined in each group and in overall patients.The participants were 329 physician-diagnosed treatment-naive patients with asthma who were divided into 187 in normal FEV1 and 142 in low FEV1 groups. Cough without dyspnea was present in 16 patients (8.6%) in the normal FEV1 group, suggesting candidates for CVA in this analysis were quite few. Improvement in symptoms after treatment was similar between both groups. But VAS scores of dyspnea were still higher in the low FEV1 group. The degree of improvement in FEV1 after ICS/LABA treatment was less in the normal FEV1 group than in the low FEV1 group, but was still evident. Peripheral eosinophil count, serum IgE, and FeNO values before treatment were lower in the normal FEV1 group. In overall patients, improvements of symptoms after treatment were significantly correlated with FEV1 changes. Improvement of dyspnea was also significantly related to peripheral eosinophil count and change of FeNO, whereas improvement of cough was not related to these T helper 2 (Th2) response markers.ResultsThe participants were 329 physician-diagnosed treatment-naive patients with asthma who were divided into 187 in normal FEV1 and 142 in low FEV1 groups. Cough without dyspnea was present in 16 patients (8.6%) in the normal FEV1 group, suggesting candidates for CVA in this analysis were quite few. Improvement in symptoms after treatment was similar between both groups. But VAS scores of dyspnea were still higher in the low FEV1 group. The degree of improvement in FEV1 after ICS/LABA treatment was less in the normal FEV1 group than in the low FEV1 group, but was still evident. Peripheral eosinophil count, serum IgE, and FeNO values before treatment were lower in the normal FEV1 group. In overall patients, improvements of symptoms after treatment were significantly correlated with FEV1 changes. Improvement of dyspnea was also significantly related to peripheral eosinophil count and change of FeNO, whereas improvement of cough was not related to these T helper 2 (Th2) response markers.Candidates for CVA among the patients with asthma with predicted FEV1 ≥90% were few. Participants with normal FEV1 respond well to ICS/LABA treatment for improvement of symptom. The change of FEV1 after treatment, and the pre-treatment blood eosinophil count, serum IgE, and FeNO were lower in normal FEV1 cases than in low FEV1 cases. These observations suggest asthmatic patients with normal FEV1, including candidates for CVA having just common mild asthma. In overall participants, symptoms of cough and dyspnea were similar, but were not identical in relation to the Th2 background.ConclusionsCandidates for CVA among the patients with asthma with predicted FEV1 ≥90% were few. Participants with normal FEV1 respond well to ICS/LABA treatment for improvement of symptom. The change of FEV1 after treatment, and the pre-treatment blood eosinophil count, serum IgE, and FeNO were lower in normal FEV1 cases than in low FEV1 cases. These observations suggest asthmatic patients with normal FEV1, including candidates for CVA having just common mild asthma. In overall participants, symptoms of cough and dyspnea were similar, but were not identical in relation to the Th2 background.
Author Ohwada, Akihiko
Kitaoka, Hiroko
Author_xml – sequence: 1
  givenname: Akihiko
  surname: Ohwada
  fullname: Ohwada, Akihiko
– sequence: 2
  givenname: Hiroko
  surname: Kitaoka
  fullname: Kitaoka, Hiroko
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39444879$$D View this record in MEDLINE/PubMed
BookMark eNpVkU1PwzAMhiM0xOdO3FGOQ6iQ7zYnBNMGSJO4ANcoTVNW1CYj6YD9e8I2EPhiy378WvJ7CAbOOwvACUYXBCOaX772VUZYVohiBxwQlOeZEIQN1jXJMKNyHwxjfEUpBCIkz_fAPpWMsSKXB0DdBO_MvNEt1LGfdxp-NP0cOh-61Kp9MLaC9nPRBN37sILvvl12FjYOYhit8a6Co-nkGZ9B47uFDoleC7T-A373j8Furdtoh9t8BJ6mk8fxXTZ7uL0fX88yQxnqM0ElLUpRI0p1YWtNCTOcmaoUJa9zLglFuqTGIMmEtFqyAouizBGvGbIsbR2Bq43uYll2tjLW9UG3ahGaToeV8rpR_yeumasX_64wZpJxLpLCaKsQ_NvSxl51TTS2bbWzfhkVxQQhLjkvEnr699jvlZ-3JuB8A5jgYwy2_kUwUmvfVPJNEaaSb_QL6-2Jvw
ContentType Journal Article
Copyright 2024 AME Publishing Company. All rights reserved.
2024 AME Publishing Company. All rights reserved. 2024 AME Publishing Company.
Copyright_xml – notice: 2024 AME Publishing Company. All rights reserved.
– notice: 2024 AME Publishing Company. All rights reserved. 2024 AME Publishing Company.
DBID AAYXX
CITATION
NPM
7X8
5PM
DOI 10.21037/jtd-24-868
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2077-6624
EndPage 5590
ExternalDocumentID PMC11494556
39444879
10_21037_jtd_24_868
Genre Journal Article
GroupedDBID 53G
AAKDD
AAWTL
AAYXX
ACGFO
ADBBV
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BMSDO
CITATION
DIK
GX1
HYE
OK1
RPM
NPM
7X8
5PM
ID FETCH-LOGICAL-c340t-63938b6f033a8efa324c54cdb6b5f759230ab3cc09469ea948168b705f40e4033
ISSN 2072-1439
IngestDate Thu Aug 21 18:31:01 EDT 2025
Fri Jul 11 09:42:34 EDT 2025
Thu Apr 03 07:05:56 EDT 2025
Tue Jul 01 02:13:50 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 9
Keywords Cough variant asthma (CVA)
mild asthma
normal forced expiratory volume in 1 second (normal FEV1)
Language English
License 2024 AME Publishing Company. All rights reserved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c340t-63938b6f033a8efa324c54cdb6b5f759230ab3cc09469ea948168b705f40e4033
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Contributions: (I) Conception and design: A Ohwada; (II) Administrative support: A Ohwada; (III) Provision of study materials or patients: A Ohwada; (IV) Collection and assembly of data: A Ohwada; (V) Data analysis and interpretation: A Ohwada; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors.
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC11494556
PMID 39444879
PQID 3120059558
PQPubID 23479
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_11494556
proquest_miscellaneous_3120059558
pubmed_primary_39444879
crossref_primary_10_21037_jtd_24_868
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-09-30
PublicationDateYYYYMMDD 2024-09-30
PublicationDate_xml – month: 09
  year: 2024
  text: 2024-09-30
  day: 30
PublicationDecade 2020
PublicationPlace China
PublicationPlace_xml – name: China
PublicationTitle Journal of thoracic disease
PublicationTitleAlternate J Thorac Dis
PublicationYear 2024
Publisher AME Publishing Company
Publisher_xml – name: AME Publishing Company
SSID ssj0000602277
Score 2.3374815
Snippet Cough variant asthma (CVA) is characterized by cough as a sole symptom and normal pulmonary function. However, it is unclear whether CVA really common among...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 5580
SubjectTerms Original
Title Bronchial asthma with normal forced expiratory volume in 1 second (FEV1) compared with low FEV1
URI https://www.ncbi.nlm.nih.gov/pubmed/39444879
https://www.proquest.com/docview/3120059558
https://pubmed.ncbi.nlm.nih.gov/PMC11494556
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ri9NAEF_0BPGL-LbngxXug1KiyT7S5KNIS5F7fGml35bNJktzPRO55rjDv96ZbB5NVTj9EsJuOgnzG6Yzs_Mg5CgNRMaMDrwosNYTqeVerMPE45GWScpsEPlYnHxyGs6X4utKrvrpbXV1SZV8ND__WFfyP6jCGuCKVbL_gGxHFBbgHvCFKyAM11thDD50gbnKF2O9rdbftYuqFmiG1mWJeLaf3XRH6U4TYYQjGG_REa4DCLPptwBjA8Ns9Ivyeow7fzFeqzWIjsnN_gHP2fpapy5Uu8nX-absz_grXW7qnXl-WTYbTbiBiTY3otVKzJ8wD4yseKBCwx1RiXf0oZRuTtO-omZNrf95lXrwjsiN1hm2wz49U7Pl8bFaTFeLu-QeAz-A74Rj3F8tdkDEkvjus1wNZk3_U099aHX85krsZ8TumBiLR-Rhw1762QH9mNzJiifk_kmT_fCUqA5v6vCmCBV1eFOHN-3xpo5tNC9oQB3e9D1i-oG2WDsCgDXF9WdkOZsuvsy9ZkCGZ7jwKw-sSx4lofU511FmNRjHRgqTJmEi7USC7e7rhBsDLnwYZxob84RRMvGlFX4m4FfPyUFRFtlLQkXEU8G1Af3OhQUbl2uGnZNsiAMFmB6Ro5aB6ofrg6LAf6z5rIDPigkFfB6Rdy1zFegpPHzSRVZebRUPMH4Zg0CMyAvH7I4QFmeD4xyPSDSAoXsAe6APd4p8XfdCB3c-FlKGh7d48SvyoJfo1-SgurzK3oBJWSVva7H6BRoAeBw
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bronchial+asthma+with+normal+forced+expiratory+volume+in+1+second+%28FEV1%29+compared+with+low+FEV1&rft.jtitle=Journal+of+thoracic+disease&rft.au=Ohwada%2C+Akihiko&rft.au=Kitaoka%2C+Hiroko&rft.date=2024-09-30&rft.issn=2072-1439&rft.volume=16&rft.issue=9&rft.spage=5580&rft_id=info:doi/10.21037%2Fjtd-24-868&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-1439&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-1439&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-1439&client=summon